Iodide

Iodide

SCHEMBL4566525

C=CCc1nccn1CC=C.I

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG

The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL207290 0.98 ADORA2B (0.32) ADORA2B
Water SCHEMBL28225074 0.96 ADORA2B (0.31) ADORA2B
Fluoride SCHEMBL28263051 0.96 ADORA2B (0.31) ADORA2B
Bromide SCHEMBL2439099 0.96 ADORA2B (0.31) ADORA2B
Hydrochloric Acid SCHEMBL1805025 0.96 ADORA2B (0.31) ADORA2B
SCHEMBL2575220 0.88
Sulfurous Acid SCHEMBL17668120 0.88 ADORA2B (0.31) ADORA2B
Acetic Acid SCHEMBL14164759 0.87 SMN1; SMN2 (0.34) ADORA2B
SCHEMBL16649431 0.85 FDPS (0.34)
Nitric Acid SCHEMBL301292 0.85 CYP2C19 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140348719-A1 PHARMACEUTICAL COMPOUND STABILIZING FILTER COMPOSITIONS AND METHODS OF MAKING AND USING SAME VERITAS BUREAU (US) 2014-11-27 US claimed
US-10475593-B2 Use of halogen derivatives of histidine as electrolytic salt in a photovoltaic dye cell CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2019-11-12 US disclosed
CN-105308016-B Process for the co-production of acetic acid and acetic anhydride 英国石油化学品有限公司 2018-03-02 CN disclosed
US-20170323732-A1 USE OF HALOGEN DERIVATIVES OF HISTIDINE AS ELECTROLYTIC SALT IN A PHOTOVOLTAIC DYE CELL UNIVERSITE DE PICARDIE JULES VERNE (FR) 2017-11-09 US disclosed
US-20140348719-A1 PHARMACEUTICAL COMPOUND STABILIZING FILTER COMPOSITIONS AND METHODS OF MAKING AND USING SAME VERITAS BUREAU (US) 2014-11-27 US disclosed
EP-2637997-A1 COPRODUCTION OF ACETIC ACID AND ACETIC ANHYDRIDE Eastman Chemical Company (US) 2013-09-18 EP disclosed
WO-2012064830-A1 COPRODUCTION OF ACETIC ACID AND ACETIC ANHYDRIDE EASTMAN CHEMICAL COMPANY (US) 2012-05-18 WO disclosed
US-7220914-B2 Zwitterionic compounds and photovoltaic cells containing same KONARKA TECHNOLOGIES, INC. (US) 2007-05-22 US disclosed
US-20050211292-A1 Zwitterionic compounds and photovoltaic cells containing same KONARKA TECHNOLOGIES, INC. (US) 2005-09-29 US disclosed
WO-2005055286-A2 ZWITTERIONIC COMPOUNDS AND PHOTOVOLTAIC CELLS CONTAINING SAME KONARKA TECHNOLOGIES, INC. (US) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170323732-A1 USE OF HALOGEN DERIVATIVES OF HISTIDINE AS ELECTROLYTIC SALT IN A PHOTOVOLTAIC DYE CELL HDHD5, HCLS1, HCN1 ADORA2B 4765/4885
US-20050211292-A1 Zwitterionic compounds and photovoltaic cells containing same VDAC1, EPCAM, VCL ADORA2B 2479/4885
US-10475593-B2 Use of halogen derivatives of histidine as electrolytic salt in a photovoltaic dye cell HDHD5, HCLS1, HCN1 ADORA2B 4765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.